The US premarket indicator for Biogen stock is up 1.8 percent at USD 273.
This in spite of Biogen's total Q3 revenue drop of 18 percent, ending at USD 2.78bn – thus over analysts' estimates of USD 2.68bn.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.